期刊
LIFE SCIENCES
卷 249, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2020.117498
关键词
Doxorubicin; Metformin; AMPK; MAPK; Cardiotoxicity
资金
- Natural Science Foundation of Zhejiang Province [LQY18H160001, LQY19H280002, LY17H310009, LQ14H260002]
- Zhejiang Provincial Bureau of Traditional Chinese Medicine [2018ZB027]
- Science and Technology Department of Zhejiang Province [2017F30001]
Aims: Doxorubicin (DOX) is an effective anthracycline anticancer drug. However, the clinical usage of it is limited due to its severe cardiotoxicity side effects. Metformin (Met) is a kind of first-line antihyperglycemic drug which has a potential protective effect on the heart , it is often used for oral treatment of type 2 diabetes. In this study, we explored whether met could attenuate cardiotoxicity induced by DOX. Materials and methods: For the sake of exploring the met protective effect and mechanism, we established the DOX-induced cardiotoxicity models both in H9C2 cells incubated with 5 mu M DOX in vitro and Sprague-Dawley rats treated with 20 mg/kg cumulative dose of DOX. Key findings: met is able to inhibit growth inhibition and apoptosis of H9C2 cells induced by DOX. The heart indexes of rats were examined to evaluate the met cardiotoxicity protection. met improved the abnormal indexes, serum markers of cardiac heart injury, echocardiography, electrocardiogram, cardiac pathology, cardiomyocyte apoptosis, and oxidative stress markers induced by DOX. Furthermore, in vivo and in vitro studies demonstrated that met protected against DOX-induced increasing cleaved caspase-3 and Bax. met also prevented the downregulation of Bcl-2, activated the AMPK pathway, and inhibited the MAPK pathway. Significance: met showed protective effects on DOX-induced cardiotoxicity by reducing oxidative stress and apoptosis, as well as regulating AMPK and MAPK signaling pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据